Abstract: The present invention relates to compositions comprising a vitamin E analog and an arsenic compound for treating hyperproliferative cells disorders such as cancer. The composition of the invention potentiates arsenic toxicity towards cancer cells and can also prevent arsenic-mediated toxicity of non-cancerous cells.
Type:
Grant
Filed:
October 4, 2006
Date of Patent:
July 22, 2014
Assignee:
Samuel Waxman Cancer Research Foundation
Inventors:
Wilson H. Miller, Zuanel Diaz Heredia, Hyman M. Schipper, Koren K. Mann
Abstract: The present invention relates, generally, to compositions for treating breast cancer, use of the compositions to sensitize breast cancer cells to treatment, and methods for treating breast cancer by administering the compositions. The compositions comprise peptides derived from the mSin3A interaction domain (SID) and derivatives thereof, as well as small molecule inhibitors (SMIs) capable of interfering with interactions between SID and the paired amphipathic helix domain 2 (PAH2) domain of the transcription repressor Sin3A. The present invention further relates to compositions for treating triple-negative breast cancer, use of the compositions to render the breast cancer cells susceptible to treatment using hormonal therapies and HER2-based therapies, and methods for treating triple-negative breast cancer by administering the compositions.
Type:
Application
Filed:
June 1, 2010
Publication date:
January 6, 2011
Applicants:
SAMUEL WAXMAN CANCER RESEARCH FOUNDATION, C/O SAMUEL WAXMAN CANCER RESEARCH FOUNDATION